23 November 2022 In General Health

BACKGROUND: Alcohol-induced hangover represents a significant, yet understudied, global hazard and a large socio-economic burden.

OBJECTIVES: The aim of this study was to investigate the effects of hydrogen (H2) on relieving drinking and hangover symptoms in 20 healthy volunteers. METHODS: In this pilot, randomized, double-blinded, placebo-controlled, matched, crossover interventional trial, participants were matched into pairs and randomly assigned. Study group 1 inhaled placebo air for 1 hr, followed by drinking 100 ml of liquor (40% alcohol) within 10 min, and then pure water. Study group 2 inhaled a mixture of H2 and O2 gas for 1 hr, followed by drinking 100 ml of liquor within 10 min, and then H2 dissolved in water. On a second intervention day (crossover) >/=1 wk later, study-group subjects were switched to the opposite order. Breath alcohol concentration (BrAC), hangover severity, and cognitive scores were measured.

RESULTS: The BrACs within the H2 group were significantly lower than those within the placebo group after 30 min, 60 min, and 90 min (P < 0.05). The H2 group reported having fewer hangover symptoms compared with the placebo group (Placebo: 77% of symptoms absent, 19.7% of mild symptoms, 2.7% of moderate symptoms, 0.7% of severe symptoms; H2: 88.6% of symptoms absent, 10% of mild symptoms, 1.3% of moderate symptoms, 0% of severe symptoms; P < 0.001). H2 treatment improved cognitive testing scores (P < 0.05), including attention and executive functions. Furthermore, consumption of H2 was negatively (beta = -13.016; 95% CI: -17.726, -8.305; P < 0.001) and female sex was positively (beta = 22.611; 95% CI: 16.226, 28.997; P < 0.001) correlated with increased BrACs. Likewise, the consumption of H2 was negatively (OR: 0.035; 95% CI: 0.007, 0.168; P < 0.001) while female sex was positively (OR: 28.838; 95% CI: 5.961, 139.506; P < 0.001) correlated with the severity of hangover symptoms.

CONCLUSIONS: H2 decreases BrACs and relieves the symptoms of hangovers.This trial was registered at China Clinical Trial Registry as ChiCTR2200059988. URL of registration: http://www.chictr.org.cn/showproj.aspx?proj=58359.

Contact us

We love your feedback. Get in touch with us.

  • Tel: +32 (0)2 230 99 70
  • Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Disclaimer

The authors have taken reasonable care in ensuring the accuracy of the information herein at the time of publication and are not responsible for any errors or omissions. Read more on our disclaimer and Privacy Policy.